Investment
Features
FeesSafety
Academy
More
Pluang+

Compare CleanSpark Inc (CLSK) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance

CleanSpark IncTrade
Charles River Laboratories Intl. IncTrade

Price performance (Past 24H)

Key statistics

CleanSpark Inc vs Charles River Laboratories Intl. Inc — how do they compare? CleanSpark Inc trades at $13.71 (market cap $3.45B), while Charles River Laboratories Intl. Inc trades at $232.4 (market cap $11.14B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 3.2× CleanSpark Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, CleanSpark Inc nearer its low. Which is the better fit depends on your goals.

CLSKCRL
Market Cap
$3.45B$11.14B
Sector
TechnologyHealth
52-Week High
$23.20$233.60
52-Week Low
$8.18$145.57
Enterprise Value
$4.31B$14.00B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

CleanSpark Inc

CleanSpark (CLSK) trades at $12.36, down 3.81% today, with a bearish technical signal and recent earnings misses. The company reported a net loss margin of -67.66% for 2026 but announced a transformative $6.6 billion 20-year AI data center lease, shifting focus from Bitcoin mining to high-performance computing. Analyst consensus remains unanimously bullish with a $21.43 price target, highlighting growth potential despite current profitability challenges.

The outlook balances high growth potential from the AI pivot against significant execution risks and persistent losses. Near-term volatility is expected as the market assesses the company's ability to monetize new contracts and achieve sustainable profitability. The stock presents a high-risk, high-reward opportunity dependent on successful business model transition.

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.

Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About CleanSpark Inc

CleanSpark is a leading Bitcoin mining company that operates high-density data centers. It focuses on using sustainable energy to power its mining fleet and provides digital infrastructure for the blockchain ecosystem.

Read more on CLSK

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL